Welcome to our dedicated page for Cigna Group SEC filings (Ticker: CI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cigna Group SEC filings document financial results, governance actions and material events for a global health company operating through Cigna Healthcare, Evernorth Health Services and related subsidiaries. Form 8-K reports cover results of operations and financial condition, Regulation FD outlook disclosures, board and committee changes, leadership succession matters and shareholder meeting results.
Proxy materials describe director elections, executive compensation, shareholder voting items, board composition and governance practices. The filing record also includes exhibits for earnings releases and Inline XBRL cover data, tying formal disclosures to the company’s pharmacy benefit services, specialty and care services, health benefits operations, compliance oversight and public-company capital structure.
The Cigna Group (CI) Chairman & CEO and director reported an open‑market purchase of 4,134 shares on 11/03/2025 at a weighted average price of $241.8762, with individual prices ranging from $241.876 to $241.97.
Following the transaction, beneficial ownership stands at 21,356 shares held directly; 157,935 shares held indirectly by trust; 440,798 shares held indirectly by a grantor retained annuity trust; and 1,782.7866 shares held indirectly via the 401(k) plan.
The Cigna Group reported stronger Q3 2025 results. Total revenues were $69,748 million, up from $63,694 million a year ago, driven by pharmacy revenues of $56,054 million. Premiums were $9,081 million. Income from operations was $2,578 million, roughly flat year over year.
Shareholders’ net income rose to $1,868 million and diluted EPS increased to $6.98 from $2.63, aided by lower medical costs ($7,842 million vs. $9,527 million) and net investment gains ($26 million vs. a loss of $921 million). The company recorded a gain on sale of businesses and reported shareholders’ comprehensive income of $1,885 million. Cash and cash equivalents were $6,025 million and long‑term debt was $30,947 million.
Cigna completed the sale of its Medicare-related businesses to HCSC, with the purchase price increased to $4.9 billion. The company recognized a Q3 pre-tax gain of $38 million and an after-tax gain of $241 million. It received approximately $4.2 billion in cash at closing and expects about $0.6 billion in Q4 2025. In September, Cigna issued $4.5 billion of senior notes and repaid a $2.0 billion term loan used to fund its investment in Shields Health Solutions. A quarterly dividend of $1.51 per share was declared for payment on December 18, 2025.
The Cigna Group furnished an update on quarterly performance. The company issued a press release announcing results for the three months ended September 30, 2025, and made it available as Exhibit 99.1.
The information was furnished, not filed, under the Securities Exchange Act of 1934. Common stock trades on the NYSE under the symbol CI. No additional financial details are included in this excerpt.
The Cigna Group announced that Retired Major General Elder Granger, M.D., will retire from its Board of Directors effective December 31, 2025.
The company said his retirement is consistent with the Board’s retirement age policy and is not the result of any disagreement with the Company. Dr. Granger informed the Board on October 15, 2025.
Brian C. Evanko, President and Chief Operating Officer, reported option exercises and open-market sales of Common Stock of Cigna Group (CI) under a Rule 10b5-1 plan. On 10/03/2025 he exercised 5,368 employee stock options at an exercise price of $139.22 and sold 5,368 shares at a reported price of $300. On 10/06/2025 he exercised an additional 901 options at $139.22. The filing shows beneficial ownership following the transactions of 52,083 shares (direct) plus 904.1848 shares held indirectly in the company 401(k).
The transactions were effected under a 10b5-1 trading plan adopted on 05/07/2025. The option grants referenced were originally issued on 03/01/2016 with vesting in three equal annual installments; the options expire on 03/01/2026 as stated.
Cigna Group (CI) filed a Form 144 disclosing a proposed sale of 5,368 common shares through Fidelity Brokerage Services LLC on 10/03/2025. The filing lists an aggregate market value of $1,610,400 and 266,928,075 shares outstanding for the issuer. The shares were acquired under an option granted on 03/01/2016 and are shown as acquired on 10/03/2025, with payment noted as cash. The filer certifies no undisclosed material adverse information and indicates no securities sold in the prior three months.
Koka Durga Prasad, Executive Vice President and Global CIO of Cigna Group (CI), filed an initial Form 3 reporting ownership after a qualifying event on 09/08/2025. The filing shows 4,324 shares of common stock held directly and five employee stock option grants covering 4,610 underlying shares (638, 634, 842, 1,137, 1,359) with exercise prices from $218.2525 to $336.475 and various exercisable/expiration dates through 2035. The form was signed by Elise Ryan, attorney-in-fact, on 09/17/2025.
The Cigna Group filed an 8-K reporting the filing of transaction-related exhibits dated September 2 and September 4, 2025. The company attached an Underwriting Agreement dated September 2, 2025 between The Cigna Group and BofA Securities, Citigroup, HSBC Securities (USA) and Morgan Stanley as representatives of the underwriters. It also included Supplemental Indenture No. 8 dated September 4, 2025 with U.S. Bank Trust Company, National Association as trustee, a legal opinion of Davis Polk & Wardwell LLP, and that firm’s consent. The filing identifies the company’s principal executive office in Bloomfield, Connecticut and trading symbol CI on the NYSE.
Kurian George, a director of The Cigna Group (CI), reported a compensation deferral into the company’s deferred compensation plan on 08/29/2025. The filing shows an acquisition of 99.7109 phantom stock units under the Deferral Plan at a recorded price of $300.87 per unit; each phantom unit is economically equivalent to one share of Cigna common stock and will be settled in cash. After the transaction the report shows 1,574.5491 shares (or phantom-equivalent units) beneficially owned by the reporting person, which includes 7.0495 units received via dividend reinvestment. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/02/2025.
David J. Brailer, EVP & Chief Health Officer of The Cigna Group (CI), reported a transaction on 08/29/2025 showing 290 shares of Cigna common stock were disposed of at a price of $300.66 per share. The filing states these shares were withheld to satisfy tax obligations upon the vesting of restricted shares, not a market sale.
After the withholding, Mr. Brailer beneficially owns 17,525 shares of Cigna common stock. The Form 4 was executed by an attorney-in-fact and filed on 09/02/2025.